{"url_path":"/sec/cocp/8-k/2026-06-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-026965-index.html","accession_number":"0001493152-26-026965","cik":"0001412486","ticker":"COCP","issuer_name":"Cocrystal Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-026965-index.html","primary_entity_key":"0001412486","primary_entity_name":"Cocrystal Pharma, Inc."},"word_count":101,"has_tables":true,"body_markdown":"****\n\n \n\n \n\n** **\n\n****\n\n**Item\n7.01 Regulation FD Disclosure**\n\n \n\nOn\nJune 3, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing James Sapirstein’s appointment\nas Chief Executive Officer. A copy of the press release is furnished as Exhibit 99.1.\n\n \n\nThe\ninformation in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities\nExchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed\nto be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act."}